BioRem (BRM) Q4 2025 earnings summary

Executive summary

• Record revenues and earnings before tax achieved for 2025, with earnings up 60% over 2024.

• Strong market response to new technologies and product offerings, driving demand and order growth.

• Investments in the Service Group have led to tangible increases in recurring revenue.

Financial highlights

• Full-year revenue grew 13% year-over-year to $42.4 million; Q4 revenue was $16.9 million, up from $9.3 million in Q4 2024.

• Net earnings for 2025 rose 60% to $4.8 million; Q4 net earnings were $2.7 million, up from $194,000 in Q4 2024.

• Gross profit for the year increased 27% to $12.8 million; Q4 gross margin reached 35%, up from 17.1% in Q4 2024.

• EBITDA for 2025 was $6.3 million, up from $4.7 million in 2024; Q4 EBITDA was $3.8 million, up from $425,000 in Q4 2024.

• Basic EPS for 2025 was $0.30, up from $0.19 in 2024; fully diluted EPS was $0.26.

Outlook and guidance

• Strong bidding activity, robust order backlog, and diverse technologies position the company for continued growth.

• Management anticipates ongoing geopolitical, tariff, and inflationary pressures in 2026 but expects a diverse supply chain and strong balance sheet to mitigate risks.